Sign up USA
Proactive Investors - Run By Investors For Investors

Q BioMed strikes development deal with Sphaera Pharma to advance toddler non-verbal disorder drug

The firm has struck a partnership with Sphaera Pharma to develop a new analog of the drug QBM-001
Q BioMed strikes development deal with Sphaera Pharma to advance toddler non-verbal disorder drug
There are around 20,000 new cases of pediatric developmental nonverbal disorder in the USA each year and a similar amount in Europe

Q BioMed Inc (OTCMKTS:QBIO) announced progress on its recently acquired candidate to prevent a non-verbal disorder related to autism in toddlers.

It has struck a partnership with Sphaera Pharma to develop a new analog of the drug QBM-001 - the license for which it acquired from the firm ASDERA in April this year.

"The goal of our collaboration with Sphaera Pharma is to put the patient first, especially since QBM-001 targets a rare subset of toddlers that become non- or minimally verbal for the rest of their lives," said Denis Corin, chief executive  of Q BioMed.

There are around 20,000 new cases of pediatric developmental nonverbal disorder in the USA each year and a similar amount in Europe.

Individually, the economic costs for toddlers that become non- or minimally verbal is US$10mln on average per person over their life.

Sphaera Pharma will use its patented platform to produce a novel analog that aims to reduce or eliminate potential side effects and can reduce the amount of product a toddler needs to take daily.

Preclinical testing is already underway, highlighted Q BioMed and a final product is scheduled to be ready by the middle of October.

This will put Q BioMed on a path to file an IND (investigational new drug) towards the end of 2017 or the beginning of 2018.

"Sphaera Pharma's platform has had great success by providing improved safety and efficacy profile for drugs being developed by biopharma companies," said Dr. Sundeep Dugar, chief executive of Sphaera Pharma.

"Being able to employ our technology to ensure a safer product that could allow these toddlers to speak is inspiring to our whole team."

View full QBIO profile View Profile

Q BioMed Inc Timeline

Related Articles

1504120610_biotechLatest.jpg
August 31 2017
The company is poised for a milestone-rich period over the next year or so
man at a micrscope
September 29 2017
The company is a specialist in the storage of stems cells from the umbilical cord, which could provide a potentially life-saving treatment for 82 blood-borne diseases
pregnant woman sitting in park
June 13 2017
The £225,000 order is from HuanZhong Biotech, Concepta’s partner in China
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use